2026 AATS专家共识:新生儿/婴儿心脏干预围术期抗血栓管理
美国胸外科协会召集多学科专家,采用改良德尔菲法制定新生儿和婴儿先天性心脏病干预围术期抗血栓管理共识。共识就34条声明达成一致,涵盖凝血系统特点、止血系统检测及抗血栓药物监测,并给出术前、术中、术后及器械相关管理推荐。
要点
- 新生儿和婴儿先心病患者止血系统与年长儿童和成人不同,需针对性评估。
- 共识涵盖凝血级联、止血异常检测及抗血栓药物监测。
- 推荐包括术前、术中、术后及短期和长期器械相关抗血栓管理。
核心结论
- 新生儿和婴儿先心病患者止血系统独特,需聚焦围术期评估和治疗。
- 共识推荐指导理解心脏手术和导管干预期间抗血栓管理的复杂交互。
研究设计与样本
- 美国胸外科协会委托多学科专家组(心脏外科、心脏内科、介入、血液、重症、药理)制定。
- 采用改良德尔菲法,就34条声明及相关图表达成共识。
主要发现
- 共识就所有34条声明及相关图表达成一致。
- 内容涉及先心病新生儿和婴儿的凝血级联、止血系统先天/获得/治疗相关异常检测及常用抗血栓药物监测。
- 推荐涵盖术前、术中、术后抗血栓管理,包括手术和器械特异性短期和长期推荐。
关键数值与推荐
- 共识就34条声明达成一致。
- 推荐涉及术前、术中、术后抗血栓管理及手术和器械特异性短期和长期管理。
临床怎么用
- 临床可依据共识对先心病新生儿和婴儿进行围术期止血评估和抗血栓管理。
- 关注手术和导管干预期间抗血栓药物的监测和短期、长期管理。
局限性
- 原文未明确报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The hemostatic system in neonates and infants with congenital heart disease is distinct as a result of developmental and disease-specific factors, necessitating population-specific periprocedural evaluation and antithrombotic management. Ongoing practice variation reflects limited evidence and highlights the need for structured guidance and further study. METHODS: To develop a more unified management strategy for periprocedural antithrombotic testing and therapy in this vulnerable population, a group of experts (cardiac surgeons, cardiologists, interventionalist, hematologists, intensivists, and pharmacologists) commissioned by the American Association for Thoracic Surgery was convened to define the basic differences in the hemostatic systems of neonates and infants compared with older children and adults and develop a framework for periprocedural antithrombotic management in neonates and infants undergoing congenital cardiac interventions using the modified Delphi methodology. RESULTS: Consensus was reached on all 34 statements and related figures and tables. These provide information specific to neonates and infants with congenital heart disease on the coagulation cascade; testing for congenital, acquired, and therapy-related abnormalities in the hemostatic system; and commonly used antithrombotic (anticoagulant and antiplatelet) agents and their monitoring. Recommendations were made on pre-, intra-, and postprocedural antithrombotic management, including procedure and device-specific recommendations both in the short and long term. CONCLUSIONS: The hemostatic system in neonates and infants with congenital heart disease is distinct from that of older children and adults and warrants focused periprocedural evaluation and therapy. These recommendations guide understanding of the complex interactions during antithrombotic management in this patient population during cardiac surgical and catheter-based interventions.
引用
- Nathan M, Kiskaddon AL, Emani S, et al. 2026 American Association for Thoracic Surgery (AATS) expert consensus statement: Antithrombotic management of neonates/infants undergoing cardiac interventions. J Thorac Cardiovasc Surg. 2026. PMID: 42097537. doi:10.1016/j.jtcvs.2026.03.617
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。